CervoMed Inc. Common Stock (CRVO) is a publicly traded Healthcare sector company. As of May 21, 2026, CRVO trades at $3.24 with a market cap of $28.15M and a P/E ratio of -1.08. CRVO moved +12.80% today. Year to date, CRVO is -58.51%; over the trailing twelve months it is -63.10%. Its 52-week range spans $1.80 to $16.94. Analyst consensus is strong buy with an average price target of $20.80. Rallies surfaces CRVO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
CervoMed’s Neflamapimod Yields 1.11-Point CDR-SB Benefit in DLB Patients: CervoMed’s Phase 2b trial data show DLB patients with plasma pTau181 under 21 pg/mL achieved a 1.11-point CDR-SB improvement (p=0.005) on neflamapimod batch B. PK/PD analyses establish a 4 ng/mL trough target and endorse a 50 mg TID regimen for the impending Phase 3.
| Metric | Value |
|---|---|
| Price | $3.24 |
| Market Cap | $28.15M |
| P/E Ratio | -1.08 |
| EPS | $-2.98 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.94 |
| 52-Week Low | $1.80 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $4.01M |
| Net Income | $-26.97M |
| Gross Margin | 0.00% |
5 analysts cover CRVO: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.80.